History
A history of accomplishments rooted in science
From our start in Copenhagen in 1999, our continued commitment to oncology has given us purpose and a drive to improve the lives of people with cancer.
It is our aspiration for the future that by 2030, our knock-your-socks-off antibody medicines (KYSO antibody medicines®) are fundamentally transforming the lives of people with cancer and other serious diseases. We strive to achieve this goal by working together as one team and building on our world-class research in antibodies to expand our capabilities beyond the lab.
While we are proud of our past accomplishments for getting us to this point, we keep our eyes and minds focused on what’s next. Our history has been powered by a dedication to antibody-based therapeutics. It is this same spirit that will guide us into the future.
Scroll down to see some of our key accomplishments, milestones and moments.
- 2022
- U.S. FDA granted orphan-drug designation to epcoritamab for the treatment of follicular lymphoma
- Regulatory submissions for epcoritamab in U.S. and Japan by Genmab and in Europe by AbbVie
- Epcoritamab Biologics License Application accepted for Priority Review by U.S. FDA
- Epcoritamab Marketing Authorization Application validated by the European Medicines Agency
- Publication by Genmab and collaboration partner AbbVie of topline results from the large B-cell lymphoma cohort of the pivotal EPCORE™ NHL-1 epcoritamab study
- Second regulatory approval for a therapy created using Genmab’s proprietary DuoBody® bispecific technology platform.
- 2021
- Genmab’s first therapy, Tivdak®(Tisotumab Vedotin-tftv), a first-in-class antibody-drug conjugate approved in the U.S. for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
- DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) approved by U.S. FDA in combination with bortezomib, cyclophosphamide, and dexamethasone for the treatment of adult patients with newly diagnosed light-chain (AL) amyloidosis
- First-ever Biologics License Application for a Genmab-owned product tisotumab vedotin, was accepted with a priority review designation by the U.S. FDA
- Kesimpta® (ofatumumab) receives European approval for the treatment of relapsing forms of multiple sclerosis in adults
- First regulatory approval for a therapy created using Genmab’s proprietary DuoBody® bispecific technology platform
- 2020
- Phase 3 study evaluating epcoritamab in patients with relapsed or refractory diffuse large B-cell lymphoma was announced
- DARZALEX® (daratumumab) in combination with carfilzomib and dexamethasone approved by U.S. FDA in relapsed or refractory multiple myeloma
- The U.S. FDA Approves Kesimpta® (ofatumumab) in Relapsing Multiple Sclerosis, first B-cell therapy that can be self-administered using Sensoready® autoinjector pen
- Genmab announces very favorable topline results from phase 2 clinical trial of tisotumab vedotin in recurrent or metastatic cervical cancer
- Genmab and AbbVie enter into broad oncology collaboration
- Subcutaneous formulation of DARZALEX® (daratumumab) approved in Europe for adult patients with multiple myeloma in all currently approved daratumumab intravenous formulation indications.
- Subcutaneous formulation of daratumumab, DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) approved by U.S. FDA for certain multiple myeloma indications
- First DuoBody® product candidate (amivantamab) awarded Breakthrough Therapy Designation by U.S. FDA
- TEPEZZA® (teprotumumab) approved in U.S. for Thyroid Eye Disease
- DARZALEX® (daratumumab) approved in Europe for use in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant (ASCT)
- 2019
- DARZALEX® sales by Janssen approach USD ~3 billion in a calendar year
- Genmab enters into a research collaboration and license agreement with CureVac AG for development of mRNA-based antibody therapeutics
- DARZALEX® approved in Europe and in the U.S. for use in combination with lenalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for ASCT
- DARZALEX® approved in the U.S. in combination with bortezomib, thalidomide and dexamethasone as treatment for patients newly diagnosed with multiple myeloma who are eligible for ASCT
- DARZALEX® approved in Japan in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma ineligible for ASCT
- Genmab becomes a dual-listed company with shares traded on Nasdaq Copenhagen and Nasdaq Global Select Market in the U.S. in landmark IPO; wins LifeStars 2019 European IPO of the Year
- Genmab signs agreement with Janssen for next-generation CD38 antibody, HexaBody®-CD38
- Genmab celebrates its 20th anniversary
- 2018
- Genmab unveils its HexElect® platform
- DARZALEX® approved in the U.S. and Europe for use in combination with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for ASCT
- Genmab enters strategic partnership with Immatics Biotechnologies GmbH to discover and develop next-generation bispecific cancer immunotherapies
- 2017
- Genmab wins Clinical Advance of the Year Award for the daratumumab CASTOR & POLLUX studies (together with Janssen) at the Scrip Awards 2017
- DARZALEX® sales reach USD 1 billion in a calendar year
- DARZALEX® approved in Japan for use in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone for the treatment of adults with relapsed or refractory multiple myeloma
- Seattle Genetics exercises option to co-develop and co-commercialize tisotumab vedotin
- DARZALEX® approved by the U.S. FDA for use in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor
- DARZALEX® receives European marketing authorization for use in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy
- 2016
- Genmab wins award for Biotech Company of the Year at the Scrip Awards 2016
- DARZALEX® approved by the U.S. FDA for use in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy
- Genmab wins award for Company of the Year at the European Mediscience Awards 2016
- DARZALEX® receives European conditional marketing authorization for heavily pre-treated or double refractory multiple myeloma
- Arzerra® (ofatumumab) approved in the U.S. for extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive chronic lymphocytic leukemia (CLL)
- Genmab wins award for Company of the Year at the BioCapital Europe conference 2016
- Arzerra® approved in the U.S. in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed CLL
- 2015
- Rights to ofatumumab transferred from GlaxoSmithKline (GSK) to Novartis
- DARZALEX® approved by the U.S. FDA for patients with multiple myeloma who have received at least three prior lines of therapy
- Genmab enters commercial agreement with Novo Nordisk for DuoBody® technology
- Genmab enters commercial DuoBody® technology agreement with BioNTech
- 2014
- Genmab enters into ADC collaboration with Seattle Genetics combining ADC technology with HuMax-AXL® (enapotamab vedotin)
- Genmab raises DKK 998 million in an international private placement
- Arzerra® in combination with chlorambucil approved by the U.S. FDA to treat previously untreated patients with CLL for whom fludarabine-based therapy is considered inappropriate
- 2013
- Genmab wins Biotech Company of the Year at the Annual Scrip Awards
- Ofatumumab receives Breakthrough Therapy Designation from the U.S. FDA
- Teprotumumab begins development in thyroid eye disease
- Daratumumab receives first Breakthrough Therapy Designation from the U.S. FDA
- Genmab establishes sponsored Level 1 American Depositary Receipt (ADR) Program in the U.S.
- 2012
- Genmab unveils its HexaBody® platform
- Genmab enters worldwide agreement with Janssen Biotech, Inc. for daratumumab
- Genmab enters DuoBody® platform collaboration with Janssen
- 2010
- Genmab enters collaboration with Lundbeck
- Genmab implements its updated three-pronged corporate strategy
- Genmab enters into collaboration with Seattle Genetics to combine ADC technology with HuMax®-TF (tisotumab vedotin)
- Genmab and GSK amend the ofatumumab collaboration agreement
- Jan van de Winkel becomes CEO
- The DuoBody® bispecific antibody technology platform is introduced
- 2009
- Arzerra® is launched by GSK in the U.S.
- First-ever Biologics License Application for a Genmab antibody is filed for ofatumumab in CLL with GSK
- 2007
- Development of ofatumumab in multiple sclerosis begins
- Genmab wins the 2007 Scrip Biotech Company of the Year award
- 2006
- Genmab and GSK sign a co-development and commercialization agreement for ofatumumab
- Genmab raises DKK 845 million in an international private placement
- 2005
- Daratumumab selected as CD38 antibody candidate
- Genmab wins the 2004 James D. Helix Award for Best International Biotech Company
- 2004
- Genmab raises DKK 478 million in an international private placement
- Genmab receives the James D. Watson Helix Award for Outstanding Performance by an International Biotechnology Company
- 2001
- Genmab enters its first major partnership, an antibody development collaboration with Roche
- 2000
- Genmab IPO in Copenhagen and Frankfurt raises DKK 1.56 billion, a European biotech record
Turning insights into medicine
See the results of innovation that is rooted in science
News, events and more
Get the latest stock information and news about Genmab
Paving the way
Get to know our senior leadership